CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma

计划入组 12 人 · 首次发布于 2021 年 3 月 24 日

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

计划入组 30 人 · 首次发布于 2015 年 12 月 11 日

Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

计划入组 26 人 · 首次发布于 2014 年 8 月 19 日

MALT-1 inhibitors (diffuse large B-cell lymphoma)

Tisagenlecleucel(Kymriah)

Rx

anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia/diffuse large B cell lymphoma)

CARGO Therapeutics

United States

Karyopharm Therapeutics

United States

Lineage Cell Therapeutics

United States

ZUMA-7 Trial Demonstrates Survival Advantage for Second-Line CAR-T Therapy in Refractory DLBCL

Epcoritamab Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Biomarker Testing Revolutionizes Treatment Approaches in Diffuse Large B-Cell Lymphoma